Valuation: BriaCell Therapeutics Corp.

Market Cap 32.23M 28.34M 26.33M 24.22M 45.41M 3.12B 46.23M 315M 123M 1.52B 121M 118M 5.28B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 14.36M 12.63M 11.73M 10.79M 20.24M 1.39B 20.6M 140M 54.72M 678M 53.91M 52.74M 2.35B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day+1.16%
1 week-2.25%
Current month+12.50%
1 month+23.40%
3 months+2.35%
6 months-13.00%
Current year-46.73%
1 week 5.02
Extreme 5.02
5.45
1 month 4.12
Extreme 4.12
5.75
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Date Insider Type Main position Quantity % Market Cap.
2/19/26 Option

Chief Technology Officer

37,700 0.6069%
2/19/26 Option

Chief Technology Officer

30,000 0.4830%
2/19/26 Option

Chief Technology Officer

30,000 0.4830%
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%-2.25%-53.39%-99.59% 31.87M
+1.23%+0.35%+51.62%+87.98% 55.27B
+5.09%+6.24%+63.15%+62.06% 54.15B
+0.25%+0.55%-19.67%-15.22% 23.22B
+0.72%-0.05%+3.84%+409.54% 23.11B
-0.51%+5.52%+30.72%-3.77% 20.33B
-0.37%+0.71%+31.36%-31.61% 17.91B
-0.77%+6.29%+33.32%+547.87% 15.76B
-2.54%-8.73%+164.11%+289.45% 15B
+1.22%-0.05%+22.58%+182.63% 13.82B
Average +0.53%-0.01%+32.76%+142.93% 23.86B
Weighted average by Cap. +1.31%+2.77%+43.53%+134.91%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.21M -3.91M -3.6M -6.75M -464M -6.87M -46.81M -18.26M -226M -17.99M -17.6M -785M -26.31M -23.14M -21.5M -19.77M -37.08M -2.55B -37.74M -257M -100M -1.24B -98.78M -96.64M -4.31B
Net Debt -862K -758K -704K -648K -1.21M -83.49M -1.24M -8.42M -3.29M -40.72M -3.24M -3.17M -141M -17.87M -15.71M -14.6M -13.43M -25.18M -1.73B -25.63M -175M -68.09M -844M -67.07M -65.62M -2.93B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-07-23 $5.220 +1.16% 2,180
26-07-22 $5.160 -1.53% 3,105
26-07-21 $5.240 +2.95% 3,387
26-07-20 $5.090 -3.23% 3,008
26-07-17 $5.260 -1.50% 1,805

Quarterly revenue - Rate of surprise